Richardson Electronics (RELL) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
19 Jan, 2026Executive summary
Q1 FY25 net sales rose 2.2% year-over-year to $53.7M, driven by strong growth in Green Energy Solutions (GES) and Healthcare, offset by declines in PMT and Canvys.
Backlog remains robust at $137.4M, with significant contributions from GES and PMT, supporting future growth.
The company maintains a debt-free balance sheet with $23.0M in cash and continues to invest in long-term strategic growth, infrastructure, and R&D.
Management anticipates year-over-year sales growth and higher profitability for FY25, supported by new product launches and market recovery.
Quarterly cash dividend of $0.06 per share declared for common stockholders.
Financial highlights
Gross margin was 30.6%, down from 32.8% year-over-year, mainly due to product mix and under absorption in PMT and GES.
Operating income was $0.3M, down from $1.5M in Q1 FY24.
Net income was $0.6M ($0.04/share), compared to $1.2M ($0.09/share) last year.
EBITDA was $1.7M, down from $2.6M in the prior year.
Cash and equivalents at quarter-end were $23.0M; positive operating cash flow for the second consecutive quarter.
Outlook and guidance
Management expects improved gross margins and sales in the second half of FY25, especially in GES and Healthcare.
Semiconductor wafer fab equipment market expected to recover, driving higher demand and improved margins.
Backlog at quarter-end was $137.4M, with expectations for strengthening through FY25.
Inventory for key legacy products will continue to grow through 2025 to support long-term demand.
Management expects existing liquidity and cash flow from operations to be sufficient for capital and working capital needs over the next twelve months.
Latest events from Richardson Electronics
- Sales and profits fell in 2024, but margin, cash flow, and backlog support a positive 2025 outlook.RELL
Q4 20242 Feb 2026 - Q3 net sales up 2.7% YoY, strong PMT/Canvys, $4.9M Healthcare loss, cash $36.7M, no debt.RELL
Q3 202516 Jan 2026 - Q2 FY25 sales up 12.1% to $49.5M, led by 129% GES growth and improved margins.RELL
Q2 202510 Jan 2026 - Q2 FY26 sales up 5.7% to $52.3M, GES up 39%, net loss narrows, $0.06 dividend declared.RELL
Q2 20268 Jan 2026 - Shareholders will vote on director elections, auditor ratification, compensation, and capital structure changes.RELL
Proxy Filing1 Dec 2025 - Proxy seeks approval for director elections, auditor, compensation, and share increases.RELL
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and executive pay are key 2024 meeting topics.RELL
Proxy Filing1 Dec 2025 - Annual meeting to elect directors, ratify auditor, and approve executive pay on October 8, 2024.RELL
Proxy Filing1 Dec 2025 - Definitive proxy statement filed for shareholder voting, with no fee required.RELL
Proxy Filing1 Dec 2025